N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3409-3418

  Kim, Myoung Sook ^a   Yamashita, Keishi ^a   Baek, Jin Hyen ^a   Park, Hannah Lui ^a   Carvalho, Andre Lopes ^a   Osada, Motonobu ^a   Hoque, Mohammad Obaidul ^a   Upadhyay, Sunil ^a   Mori, Masaki ^b   Moon, Chulso ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B;

APOPTOSIS; ARTICLE; CANCER INHIBITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

APOPTOSIS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 33645734603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1608     Document Type: Article

References (58)

1. Jones P, Veenstra G, Wade P, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-91.
2. Nan X, Ng H, Jonson C, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (Lond) 1998;393:386-9.
3. Herman J, Baylin S. Gene silencing in cancer in association with promoter hypermethylation. N Eng J Med 2003;349:2042-54.
4. Feinberg A, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 1983;111:47-54.
5. Feinberg A, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature (Lond) 1983;301:89-92.
6. Cameron E, Bachman K, Myohanen S, Herman J, Baylin S. Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 1999;21:103-7.
7. Presant C, Valeriote F, Vietti T. Biological characterization of a prolonged antileukemic effect of 5-azacytidine. Cancer Res 1977;37:376-81.
8. Belinsky S, Klinge D, Stidley C, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003;64:7089-93.
9. Boehning D, Snyder S. Novel neural modulators. Annu Rev Neurosci 2003;26:105-31.
10. Moriyoshi K, Masu M, Ishii T, Shigemoto R, Mizuno N, Nakanishi S. Molecular cloning and characterization of the rat NMDA receptor. Nature (Lond) 1991;354:31-7.
11. Nakazawa K, McHugh T, Wilson M, Tonegawa S. NMDA receptors, place cells, and hippocampal spatial memory. Nat Rev Neurosci 2004;5:361-72.
12. Grozdanovic Z, Gossrau R. Colocalization of nitric oxide synthase I (NOS I) and NMDA receptor subunit 1 (NMDAR-1) at the neuromuscular junction in rat and mouse skeletal muscle. Cell Tissue Res 1998;291:57-63.
13. Lin YJ, Bovetto S, Carver JM, Giordano T. Cloning of the cDNA for the human NMDA receptor NR2C subunit and its expression in the central nervous system and periphery. Brain Res Mol Brain Res 1996;43:57-64.
14. Gonzalez-Cadavid NF, Ryndin I, Vernet D, Magee TR, Rajfer J. Presence of NMDA receptor subunits in the male lower urogenital tract. J Androl 2000;21:566-78.
15. Nahm WK, Philpot BD, Adams MM, et al. Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol 2004;200:309-17.
16. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 1994;12:529-40.
17. Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N. Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 1994;347:150-60.
18. Li JH, Wang YH, Wolfe BB, et al. The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 1999;19:4180-8.
19. Kutsuwada T, Sakimura K, Manabe T, et al. Impairment of suckling response, trigeminal neuronal pattern formation, and hippocampal LTD in NMDA receptor ε2 subunit mutant mice. Neuron 1996;16:333-44.
20. Forrest D, Yuzaki M, Soares HD, et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 1994;13:325-38.
21. Sakimura K, Kutsuwada T, Ito I, et al. Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor ε1 subunit. Nature 1995;373:151-5.
22. Lamprecht R, LeDoux J. Structural plasticity and memory. Nat Rev Neurosci 2004;5:45-54.
23. 2+-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med 2002;8:971-8.
24. Rush LJ, Raval A, Funchain P, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res 2004;64:2424-33.
25. Sinclair PB, Sorour A, Martineau M, et al. A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Res 2004;64:4089-98.
26. Mandard A, Hainaut P, Hollstein M. Genetic steps in the development of squamous cell carcinoma of the esophagus. Mutat Res 2000;462:335-42.
27. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
28. Tanaka H, Shimada Y, Harada H, et al. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 1998;58:3429-34.
29. Merlo A, Herman J, Mao L, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
30. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-b, RASSF1A, FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;64:3724-8.
31. Yamashita K, Mimori K, Inoue H, Mori M, Sidransky D. A tumor suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-8.
32. Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 2001;22:1615-23.
33. 6-methylguanine-DNA methyltransferase by promoter hypermethylation and its relation to p53 mutations in esophageal squamous cell carcinoma. Carcinogenesis 2003;24:1039-44.
34. Yamashita K, Upadhay S, Osada M, et al. Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-500.
35. Hardingham G, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathway. Nat Neurosci 2002;5:405-14.
36. Anegawa N, Guttmann R, Grand E, Anand R, Lindstrom J, Lynch D. N-methyl-D-aspartate receptor mediated toxicity in nonneuronal cell lines: characterization using fluorescent measures of cell viability and reactive oxygen species production. Mol Brain Res 2000;77:163-75.
37. Lin J, Beerm DG. Molecular biology of upper gastrointestinal malignancies. Semin Oncol 2004;31:476-86.
38. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
39. Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000;92:1805-11.
40. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
41. Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in nonneoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001;93:1747-52.
42. Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002;62:371-5.
43. Harden S, Sanderson H, Goodman S, et al. Quantitative GSTP1 methylation and the detection of prostate adenocarcinoma in sextant biopsies. J Natl Cancer Inst 2003;95:1634-7.
44. Hoque M, Begum S, Topalogu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-7.
45. Li Q-L, Ito K, Sakakura CF, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113-24.
46. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.
47. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from lung tumor suppressor locus 3p21.3. Nat Genet 2000;25:315-19.
48. Suzuki H, Gabrielson E, Chen W, et al. A genomic screen for genes up-regulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
49. Suzuki H, Watkins D, Jair K, Schuebel K, et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004;36:417-22.
50. Feltus F, Lee E, Castello J, Plass G, Vertino P. Predicting aberrant CpG island methylation. Proc Natl Acad Sci USA 2003;100:12253-8.
51. Kornau H, Schenker L, Kenned M, Seeburg P. Domain interaction between NMDA receptor subunits and the postsynaptic density protein PSD-95. Science 1995;269:1937-40.
52. Bacon KB, Premack BA, Gardner P, Schall TJ. Activation of dual T cell signaling pathways by the chemokine RANTES. Science 1995;269:1727-30.
53. Ludford-Menting M, Thomas S, et al. A functional interaction between CD46 and DLG4. J Biol Chem 2002;277:4477-84.
54. Azim A, Knoll J, Marfatia S, Peel D, Bryant P, Chishti A. DLG1: chromosome location of the closest human homologue of the Drosophila discs large tumor suppressor gene. Genomics 1995;30:613-6.
55. Ohshiro T, Yagami T, Zhang C, Matsuzaki F. Role of cortical tumour-suppressor proteins in asymmetric division of Drosophila neuroblast. Nature (Lond) 2000;408:593-6.
56. Peng C, Manning L, Albertson R, Doe C. The tumour-suppressor genes Igl and Dlg regulate basal protein targeting in Drosophila neuroblasts. Nature (Lond) 2000;408:596-600.
57. Ning K, Pei L, Liao M, et al. Dual neuroprotective signaling mediated by down-regulating two distinct phosphatase activities of PTEN. J Neurosci 2004;24:4052-60.
58. Yanai H, Satoh K, Matsumine A, Akiyama T. The colorectal tumour suppressor APC is present in the NMDA-receptor-PSD-95 complex in the brain. Genes Cells 2000;5:815-22.